The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...
Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who ...
Several years ago, my dad was diagnosed with pulmonary fibrosis. The news was a shock. At 84 years old, Daddy had been ...
Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.
Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.
Researchers reveal how targeting HIF2 could transform the treatment of idiopathic pulmonary fibrosis (IPF), offering hope for ...
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...
Pulmonary fibrosis in patients with COVID-19 tends to resolve, while idiopathic pulmonary fibrosis always progresses.
SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX), a biotechnology company focused on fibrotic diseases with a market capitalization of $674 million, has named Delphine Imbert, Ph.D., as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback